Vila Nova De Famalicao

Researchers are evaluating a new algorithm-assisted subjective refraction software designed specifically for children aged 6 to 12 years. This software aims to standardize the refraction assessment process, which currently depends on the Eye Care Specialist and lacks consistency. Two software versions are being tested: version A, which covers the full subjective refraction process, and version B, which adds extra steps to help manage the child's attention and cooperation. The study compares these new software results against conventional subjective refraction methods performed with the Vision-R700 phoropter. The trial consists of two phases. In phase A, the accuracy of subjective refraction measurements (sphere, cylinder, axis, visual acuity) using Kids refraction software version A with either Vision-R or Vision-S devices is compared to conventional subjective refraction with Vision-R in non-cycloplegic conditions. Phase B repeats this comparison with Kids refraction software version B, which includes additional steps to aid child cooperation. Various interventions include non-cycloplegic and cycloplegic objective and subjective refraction methods performed with different devices and phoropters. Participants will undergo multiple refraction assessments at enrollment (Day 1) and six months later, using both versions of the software and conventional methods. Visual acuity and refraction parameters are recorded over approximately 7.5 months. Assessments include using the Kids refraction software with Vision-R and Vision-S devices, conventional methods, and retinoscopy, both with and without cycloplegia. The study monitors agreement between methods and collects data on spherical, cylindrical, and axis values along with visual acuity to evaluate software performance and consistency.

Researchers are collecting detailed information about patients with venous thromboembolism (VTE), which includes blood clots in veins such as deep-vein thrombosis and pulmonary embolism. The project aims to improve doctors' understanding of VTE, especially in patients often excluded from clinical trials, like pregnant women, elderly individuals, cancer patients, and those with other complex health issues. The goal is to reduce deaths, clot recurrence, bleeding problems, and artery-related events by sharing this knowledge widely. The study involves gathering extensive data on each patient's health status, treatments, and outcomes during the first three months of therapy. This registry is available online to help doctors quickly find information on patients with similar medical profiles and make informed decisions about managing high-risk individuals. There are no specific interventions being tested; instead, the focus is on collecting real-world patient data. Participants provide informed consent and are followed for at least three years to monitor for new clot events and complications. Researchers track recurrences of VTE, bleeding episodes, and deaths, aiming to create tools that predict which patients are most at risk for problems. This ongoing data collection supports improving care and guiding treatment decisions for diverse patient groups over time.